Loading...
ZYDUSLIFE Zydus Lifesciences Ltd Investor Conferences Announcement
Back
Zyds
ZYDS
Zydus Lifesciences Ltd
(ZYDUSLIFE)
Follow
FY2025 Announcement
View More
Back
Zyds
ZYDS
Zydus Lifesciences Ltd
(ZYDUSLIFE)
Follow
FY2025 Announcement
Filing:
Announcement
Published on:
13 May '25
EIR Received
14 May '25
Earnings Call Details
13 May '25
FDA Approval
8 May '25
Management Change
30 Apr '25
FDA Approval
30 Apr '25
USFDA Inspection Closure
26 Apr '25
Stake Acquisition
25 Apr '25
Acquisition Update
25 Apr '25
Strategic Partnership
17 Apr '25
Patent Litigation Update
17 Apr '25
Tender Offer Announcement
17 Apr '25
Investment in Feldan
16 Apr '25
Patent Litigation Update
16 Apr '25
USFDA Approval
11 Apr '25
New Subsidiary France
11 Apr '25
Dematerialization Compliance
9 Apr '25
Acquisition Update
28 Mar '25
Share Certificate Loss
28 Mar '25
FDA Approval Received
18 Mar '25
FDA Approval
16 Mar '25
USFDA Inspection Closure
14 Mar '25
Lost Share Certificates
13 Mar '25
Investment in Illexcor
12 Mar '25
USFDA Approval
12 Mar '25
Acquisition Plans
11 Mar '25
Investor Conference
11 Mar '25
Major Acquisition
11 Mar '25
USFDA Approval
10 Mar '25
Share Certificate Loss
8 Mar '25
Revised ESG Score
5 Mar '25
FDA Approval Received
5 Mar '25
Launch of ANVIMO
5 Mar '25
Combination Vaccine Develop...
4 Mar '25
GST Demand Notice
3 Mar '25
Vaccine Launch
26 Feb '25
USFDA Approval
22 Feb '25
Investor Conference
19 Feb '25
USFDA Inspection Closure
14 Feb '25
New Product Agreement
14 Feb '25
USFDA Inspection Closure
14 Feb '25
Partnership Announcement
12 Feb '25
Investor Conference
12 Feb '25
Earnings Call Transcript
11 Feb '25
Management Changes
10 Feb '25
Financial Results Published
6 Feb '25
ESG Rating Update
6 Feb '25
Investor Call Update
5 Feb '25
Financial Results Q3
5 Feb '25
Q3 Earnings Presentation
5 Feb '25
25 Years Celebration
30 Jan '25
Share Certificate Loss
29 Jan '25
Earnings Call Notice
27 Jan '25
Padma Bhushan Award
26 Jan '25
GST Demand Notice
25 Jan '25
USFDA Designation Granted
22 Jan '25
GST Demand Notice
21 Jan '25
USFDA Approval
18 Jan '25
Compliance Confirmation
11 Jan '25
Loss of Share Certificates
9 Jan '25
Zydus-CVS Agreement
7 Jan '25
FDA Drug Review
7 Jan '25
ESG Rating Update
4 Jan '25
Management Change
3 Jan '25
Credit Rating Update
30 Dec '24
Acquisition Update
27 Dec '24
FDA Approval
19 Dec '24
Equity Disinvestment
17 Dec '24
Equity Disinvestment
16 Dec '24
GST Demand Notice
29 Nov '24
Lost Share Certificate
26 Nov '24
Earnings Call Transcript
19 Nov '24
Financial Results Update
13 Nov '24
Investor Call Update
12 Nov '24
Financial Results Q2 FY25
12 Nov '24
Investor Presentation
12 Nov '24
Q2 FY25 Earnings Call
1 Nov '24
Nesher Merger Approval
24 Oct '24
WHO Prequalifies Vaccine
23 Oct '24
FDA Approval Received
17 Oct '24
New Clinical Trials
14 Oct '24
USFDA Approval
10 Oct '24
Dematerialization Compliance
8 Oct '24
FDA Approval Awarded
2 Oct '24
Share Certificate Loss
1 Oct '24
EIR Received
1 Oct '24
Tax Credit Dispute
29 Sep '24
FDA Approval Received
28 Sep '24
New Drug Development
27 Sep '24
Investor Conference
18 Sep '24
Business Acquisition
17 Sep '24
Investor Plant Visit
16 Sep '24
Exclusive Licensing Agreement
13 Sep '24
Lost Share Certificate
11 Sep '24
Clinical Trial Success
10 Sep '24
Tax Demand Order
7 Sep '24
USFDA Warning Letter
3 Sep '24
Tax Demand Notice
1 Sep '24
Tax Demand Notice
30 Aug '24
Tax Credit Order
30 Aug '24
USFDA Warning Letter
30 Aug '24
Tax Demand Order
30 Aug '24
FDA Approval
30 Aug '24
Equity Stake Acquisition
30 Aug '24
Regulatory Action
29 Aug '24
Investor Conference
28 Aug '24
Tax Demand Order
28 Aug '24
FDA Approval Received
27 Aug '24
Investor Presentation
27 Aug '24
Stake Acquisition
23 Aug '24
Zydus Acquires Sterling
23 Aug '24
Investor Conference
21 Aug '24
Tax Credit Order
20 Aug '24
Tax Demand Order
20 Aug '24
Earnings Call Transcript
17 Aug '24
Tax Demand Order
13 Aug '24
Financial Results Publication
10 Aug '24
Director Change
9 Aug '24
Investor Call Outcome
9 Aug '24
Revised Code
9 Aug '24
Financial Results Announcement
9 Aug '24
Investor Presentation
9 Aug '24
USFDA Approval for Valbenaz...
9 Aug '24
Tax Credit Issue
8 Aug '24
Share Certificate Loss Notice
6 Aug '24
Product Approval in Mexico
31 Jul '24
Receipt of Penalty Order
26 Jul '24
Financial Results Announcement
23 Jul '24
USFDA Approval for Valsarta...
23 Jul '24
Zydus Lifesciences Approval...
22 Jul '24
Newspaper Notice Publication
19 Jul '24
FDA Inspection Completion
19 Jul '24
FDA Approval
19 Jul '24
FDA Inspection Update
18 Jul '24
Newspaper Publication
18 Jul '24
Patent Licensing Agreement
17 Jul '24
AGM Notification
12 Jul '24
Regulatory Action
12 Jul '24
Drug Approval
10 Jul '24
USFDA Approval
10 Jul '24
Approval Received
10 Jul '24
Equity Shares Dematerializa...
10 Jul '24
Newspaper Publication
5 Jul '24
FDA Approval
4 Jul '24
Rectification Order
1 Jul '24
Announcement
28 Jun '24
Newspaper Publication
20 Jun '24
Investor Meeting
16 Jun '24
Medication Approval
14 Jun '24
Acquisition Announcement
31 May '24
Completion of Clinical Trial
24 May '24
Earnings Call Transcript
23 May '24
FDA Approval
22 May '24
Financial Results Publication
18 May '24
Investor Call Outcome
17 May '24
Compliance Submission
17 May '24
Financial Results Announcement
17 May '24
investor presentation
17 May '24
Appointment of Director
17 May '24
Exclusive Licensing Agreement
17 May '24
Newspaper Publication
16 May '24
FDA Approval
11 May '24
Earnings Call
10 May '24
Zydus Lifesciences Trial Co...
9 May '24
Approval from USFDA for Dap...
9 May '24
Stake Sale Update
6 May '24
Zokinvy Acquisition
4 May '24
Rights Acquisition
4 May '24
Announcement of Disinvestment
2 May '24
Correction Disclosure
1 May '24
Correction Disclosure
1 May '24
Tax Dispute
1 May '24
Tax Demand Order
1 May '24
Tax Demand Order
1 May '24
Tax Demand Notice
1 May '24
Tax Dispute
1 May '24
Tax Issue
1 May '24
Tax Issue
30 Apr '24
Received Demand Order-In-Or...
29 Apr '24
Tax Demand Notice
29 Apr '24
Newspaper Publication
27 Apr '24
USFDA Approval for Tretinoi...
26 Apr '24
Regulatory Action
25 Apr '24
USFDA Inspection
24 Apr '24
Drug Application in China
23 Apr '24
Zydus product launch announ...
22 Apr '24
Therapeutics Approval
20 Apr '24
Certificate Submission
9 Apr '24
Equity Shares Cancellation ...
8 Apr '24
Compliance Certificate
4 Apr '24
Name Approval
1 Apr '24
Disclosure of Equity Shares
29 Mar '24
Disclosure of Share Sale
29 Mar '24
Disclosure
29 Mar '24
Disclosure
28 Mar '24
Equity Shares Sale
28 Mar '24
Equity Sale Disclosure
28 Mar '24
FDA Inspection Update
27 Mar '24
Disclosure Under PIT Regula...
27 Mar '24
Equity Shares Sale
24 Mar '24
Equity Share Sale
23 Mar '24
USFDA Approval
23 Mar '24
Insider Trading Disclosure
22 Mar '24
Equity Buyback Correction
19 Mar '24
Extinguishment of Shares
18 Mar '24
Extinguishment
18 Mar '24
Insider Trading Disclosures
18 Mar '24
USFDA Approval
16 Mar '24
Buyback Announcement
15 Mar '24
FDA Approval for Chlorproma...
14 Mar '24
USFDA Approval
14 Mar '24
Product Launch
13 Mar '24
Tax Demand Order
12 Mar '24
FDA Inspection Outcome
10 Mar '24
USFDA Approval
7 Mar '24
Investor Meeting
1 Mar '24
Buyback of Shares
28 Feb '24
Buyback Offer Letter
27 Feb '24
WHO Prequalification Approval
24 Feb '24
Incorporation in UAE
22 Feb '24
USFDA Approval
16 Feb '24
Earnings Call Transcript
14 Feb '24
Investor Conference
14 Feb '24
Buyback Announcement
13 Feb '24
Board Resolution-Buyback
12 Feb '24
Board Resolution Buyback
12 Feb '24
Publication of Financial Re...
10 Feb '24
Investor Call
9 Feb '24
Update on Buyback
9 Feb '24
USFDA Approval
9 Feb '24
Financial Results and Buyba...
9 Feb '24
Investor Presentation
9 Feb '24
Buy back
9 Feb '24
USFDA Approval
8 Feb '24
Investor Conference
7 Feb '24
Demand Notice - CGST Jabalpur
30 Jan '24
Earnings Call
30 Jan '24
Product Launch
30 Jan '24
Approval for Gabapentin Tab...
25 Jan '24
Licensing Agreement
19 Jan '24
FDA Approval
17 Jan '24
Certificate Confirmation
8 Jan '24
Newspaper Advertisement
6 Jan '24
Notice of Demand
4 Jan '24
Credit Ratings
3 Jan '24
Announcement
3 Jan '24
Tax Demand Order
3 Jan '24
Assessment Order on Input T...
3 Jan '24
GST Demand Order
1 Jan '24
Assessment Order
29 Dec '23
Regulatory Action
29 Dec '23
GST Demand Order
27 Dec '23
Tax Demand Notice
26 Dec '23
Inspection observations
22 Dec '23
Newspaper Publication
21 Dec '23
Dissolution Of Wholly Owned...
18 Dec '23
Phase II clinical trial of ...
16 Dec '23
USFDA Approval
16 Dec '23
USFDA Approval
15 Dec '23
FDA Approval
14 Dec '23
GST Demand Notice
13 Dec '23
Email ID Change
12 Dec '23
Licensing Agreement
11 Dec '23
GST Demand Order
6 Dec '23
USFDA Approval
6 Dec '23
Asset Transfer
6 Dec '23
Approval for Ivabradine Tab...
1 Dec '23
Transcript Release
11 Nov '23
Newspaper Publication
11 Nov '23
Licensing Agreement
10 Nov '23
Publication of Financial Re...
8 Nov '23
Investor Conferences
7 Nov '23
Financial Performance
7 Nov '23
Investor Presentation
7 Nov '23
Acquisition Completed
6 Nov '23
USFDA Approval
6 Nov '23
Licensing Agreement
3 Nov '23
Joint Promotion Agreement
2 Nov '23
Earnings Call
1 Nov '23
Acquisition Agreement Execu...
31 Oct '23
Acquisition of LiqMeds Group
31 Oct '23
Acquisition
31 Oct '23
Licensing Agreement
30 Oct '23
Newspaper Publication
28 Oct '23
Clinical Trial Initiation
25 Oct '23
FDA approval for ZITUVIOTM
20 Oct '23
Newspaper Publication
17 Oct '23
Appointment
16 Oct '23
Certificate under Reg. 74 (...
9 Oct '23
US FDA Approval
6 Oct '23
Newspaper Publication
5 Oct '23
Phase 1 Clinical Trials
29 Sep '23
Investor Conference
20 Sep '23
Product Approval
20 Sep '23
EIR Report Received
19 Sep '23
Acquisition of equity stake
18 Sep '23
Investor Presentation
17 Sep '23
FDA approval
15 Sep '23
Announcement
13 Sep '23
Investor Conference
13 Sep '23
Incorporation of Wholly Own...
8 Sep '23
USFDA Approval
1 Sep '23
FDA Approval
31 Aug '23
Investor Conference
31 Aug '23
Newspaper Publication
29 Aug '23
Product Launch
25 Aug '23
Approval from USFDA
24 Aug '23
Equity, Debt, VC, Private E...
24 Aug '23
Equity acquisition
22 Aug '23
Announcement
18 Aug '23
Financial Statements
12 Aug '23
Analyst Calls
11 Aug '23
Financial Statements
11 Aug '23
Presentation
11 Aug '23
Investor Meetings
10 Aug '23
Asset Acquisitions
8 Aug '23
Schedule Change
4 Aug '23
Resignations
3 Aug '23
Increase in Dividend Rate
3 Aug '23
Financial Statements
1 Aug '23
Equity, Debt, VC, Private E...
27 Jul '23
Operational Disruption
27 Jul '23
Secondary Offerings
21 Jul '23
Merger of Equals
20 Jul '23
Financial Statements
15 Jul '23
Financial Statements
11 Jul '23
Post-Market Surveillance
7 Jul '23
Analyst Calls
5 Jul '23
Announcement
5 Jul '23
US FDA Inspection
4 Jul '23
US FDA Inspection
3 Jul '23
Investor Meetings
29 Jun '23
Product Launches
28 Jun '23
Asset Acquisitions
23 Jun '23
Drug Approval
19 Jun '23
Injectables Manufacturing
13 Jun '23
New Product Launches
13 Jun '23
Product Approvals
13 Jun '23
Drug Approval
13 Jun '23
New Product Launches
10 Jun '23
Product Launch
9 Jun '23
Rebranding
8 Jun '23
Drug Approval
7 Jun '23
Voluntary Delisting
6 Jun '23
Participation in Conference
6 Jun '23
Manufacturing Facility Insp...
2 Jun '23
Earnings Guidance
24 May '23
Financial Statements Public...
19 May '23
Audio recording availability
18 May '23
Financial Statements Disclo...
18 May '23
Financial Statements
18 May '23
Appointments
18 May '23
Earnings Report
18 May '23
Financial Statements
18 May '23
Drug Approval
17 May '23
Earnings Calls
13 May '23
Regulatory Compliance
10 May '23
New Product Launches
4 May '23
External Links:
BSE
NSE
Data:
Download
AI Assistant
Close
Zydus Lifesciences Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.